RBC Capital Initiates Coverage On Abbott Laboratories with Outperform Rating, Announces Price Target of $146
RBC Capital analyst Shagun Singh initiates coverage on Abbott Laboratories (NYSE:ABT) with a Outperform rating and announces Price Target of $146.
Full List Of CNBC Investing Club Portfolio (List In Body Of Headline) BZ NOTE: These Stocks Have Seen Volume As They Are Mentioned On Program
ABT
ABBV
AMD
GOOGL
AMZN
AAPL
AEO
BA
BCOM
CSCO
CVX
COST
DIS
DD
M
LLY
EL
HON
LIN
MRVL
FB
MSFT
MS
NLOK
NUE
NVDA
PYPL
CRM
WMT
UNP
WFC
WYNN
UPSABT
ABBV
AMD
GOOGL
AMZN
AAPL
AEO
BA
BCOM
CSCO
CVX
COST
DIS
Dupont
M
LLY
EL
HON
LIN
MRVL
Here’s How Much $100 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today
Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 12.02% on an annualized basis.
‘Senate votes to repeal key Biden administration vaccine and testing policy’ -Earlier Washington Post Report
https://www.washingtonpost.com/us-policy/2021/12/08/republicans-vaccine-congress-coronavirus/
White House Chief Of Staff Ronald Klain Says President Biden Will Announce Today ‘FREE and RELIABLE’ COVID At Home Tests
https://twitter.com/WHCOS/status/1466404937525567496?s=20
Vice President Of Abbott Laboratories Makes $1.0M Sale
Philip P Boudreau, Vice President at Abbott Laboratories (NYSE:ABT), made a large insider sell on October 25, according to a new SEC filing.
Where Abbott Laboratories Stands With Analysts
Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
